HomeCompareCDTX vs QSR

CDTX vs QSR: Dividend Comparison 2026

CDTX yields 0.90% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QSR wins by $3.7K in total portfolio value
10 years
CDTX
CDTX
● Live price
0.90%
Share price
$221.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.0K
Annual income
$95.80
Full CDTX calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.90
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$386.99
Full QSR calculator →

Portfolio growth — CDTX vs QSR

📍 QSR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDTXQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDTX + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDTX pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDTX
Annual income on $10K today (after 15% tax)
$76.79/yr
After 10yr DRIP, annual income (after tax)
$81.43/yr
QSR
Annual income on $10K today (after 15% tax)
$288.70/yr
After 10yr DRIP, annual income (after tax)
$328.94/yr
At 15% tax rate, QSR beats the other by $247.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDTX + QSR for your $10,000?

CDTX: 50%QSR: 50%
100% QSR50/50100% CDTX
Portfolio after 10yr
$22.8K
Annual income
$241.39/yr
Blended yield
1.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

CDTX
Analyst Ratings
1
Strong
7
Buy
3
Hold
Consensus: Buy
Price Target
$181.50
-18.0% upside vs current
Range: $150.00 — $221.50
Altman Z
32.6
Piotroski
2/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.4% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDTX buys
0
QSR buys
0
No recent congressional trades found for CDTX or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDTXQSR
Forward yield0.90%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$21.0K$24.7K
Annual income after 10y$95.80$386.99
Total dividends collected$933.00$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusBuyBuy
Analyst price target$181.50$81.57

Year-by-year: CDTX vs QSR ($10,000, DRIP)

YearCDTX PortfolioCDTX Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$10,790$90.34$11,037$336.93$247.00QSR
2$11,637$91.11$12,154$344.76$517.00QSR
3$12,543$91.82$13,357$351.99$814.00QSR
4$13,514$92.50$14,651$358.62$1.1KQSR
5$14,553$93.14$16,041$364.68$1.5KQSR
6$15,665$93.74$17,534$370.18$1.9KQSR
7$16,856$94.30$19,136$375.14$2.3KQSR
8$18,131$94.83$20,856$379.58$2.7KQSR
9$19,495$95.33$22,699$383.52$3.2KQSR
10$20,956$95.80$24,675$386.99$3.7KQSR

CDTX vs QSR: Complete Analysis 2026

CDTXStock

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Full CDTX Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this CDTX vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDTX vs SCHDCDTX vs JEPICDTX vs OCDTX vs KOCDTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.